ArticleNeuro-oncology advances
Alzheimer's disease neuropathological change in younger individuals with IDH-mutant glioma.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With aging populations, the incidence of brain tumors and neurodegenerative diseases is rising. Recently, Alzheimer's disease neuropathological change (ADNC) has been documented in the tumor-adjacent cortex of 50% of patients with glioblastoma, with isolated hyperphosphorylated tau (pTau) deposits already present in younger individuals. This study extends ADNC screening to younger patients with IDH-mutant glioma, focusing on pTau and amyloid beta (Abeta) deposits, microglial activation, and amyloid precursor protein (APP) expression in the context of cortical tumor cell infiltration. Material and Methods: We included 85 patients with IDH-mutant gliomas (37 astrocytomas, median age: 39; 48 oligodendrogliomas, median age: 50) classified as CNS-WHO grades 2-3. Tumor-adjacent cortex was immunohistochemically stained for b-A4, t-AT8, NeuN, APP, Ki67, and Iba1, and cells were quantified using Matlab and QuPath script. Longitudinal samples were available for 15 patients. Results: The median cell density in the tumor-adjacent cortex was significantly higher in glioma patients (astrocytoma: 1395/mm Conclusion: Our study reveals an unexpectedly high prevalence of ADNC, particularly isolated pTau deposits, in the tumor-adjacent cortex of younger individuals with IDH-mutant glioma. These findings suggest tumor-driven tau accumulation, prompting further research into potential long-term cognitive effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.